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Abstract
Background: The trial aims to evaluate whether neonatal mortality can be reduced through
systemic changes to the provision and promotion of healthcare. Neonatal mortality rates in India
are high compared to other low income countries, and there is a wide variation of rates across
regions. There is evidence that relatively inexpensive interventions may be able to prevent up to
75% of these deaths. One area with a particularly high rate is Mahabubnagar District in Andhra
Pradesh, where neonatal mortality is estimated to be in the region of 4–9%. The area suffers from
a vicious cycle of both poor supply of and small demand for health care services. The trial will assess
whether a package of interventions to facilitate systemic changes to the provision and promotion
of healthcare may be able to substantially reduce neonatal mortality in this area and be cost-
effective. If successful, the trial is designed so that it should be possible to substantially scale up the
project in regions with similarly high neonatal mortality throughout Andhra Pradesh and elsewhere.
Methods/Design: This trial will be a cluster-randomised controlled trial involving 464 villages in
Mahabubnagar District. The package of interventions will first be introduced in half of the villages
with the others serving as controls. The trial will run for a period of three years. The intervention
in the trial has two key elements: a community health promotion campaign and a system to contract
out healthcare to non-public institutions. The health promotion campaign will include a health
education campaign, participatory discussion groups, training of village health workers and
midwives, and improved coordination of antenatal services. The intervention group will also have
subsidised access to pregnancy-related healthcare services at non-public lth centres (NPHCs).
The primary outcome of the trial will be neonatal mortality. Secondary outcomes will include age
at and cause of neonatal death, neonatal morbidity, maternal mortality and morbidity, health service
usage, costs and several process and knowledge outcomes.
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Discussion:  The trial will be run by independent research and service delivery arms and
supervised by a trial steering committee. A data monitoring committee will be put in place to
monitor the trial and recommend stopping/continuation according to a Peto-Haybittle rule. The
primary publication for the trial will follow CONSORT guidelines for cluster randomised
controlled trials. Criteria for authorship of all papers, presentations and reports resulting from the
study will conform to ICMJE standards.
Trial Registration: Current Controlled Trials ISRCTN24104646
Background
Research justification and relevant literature
Neonatal mortality accounts for almost 40% of all deaths
of children under five worldwide, approximately 3.9 mil-
lion deaths annually [1]. (neonatal mortality and other
terms of interest are defined in Table 1 in the appendix)
The Lancet Neonatal Survival Series asserts that a very small
group of causes – including severe infection, prematurity,
and birth asphyxia/childbirth complications – lead to the
vast majority of these deaths [2]. These and the other
major causes of neonatal mortality result in three million
newborn deaths that "could be prevented annually by
improving access to the low-cost, low-tech interventions
that are not currently reaching those most in need," [3].
Our trial tests whether a functional, cost-effective and scal-
able programme, based on interventions suggested by this
literature, can reduce neonatal mortality.
The methods for implementing this programme are also
derived from the public health literature. There is a grow-
ing body of evidence showing the potential efficacy of
community interventions to address public health prob-
lems and disseminate health knowledge, however there
exists a large research gap in the literature evaluating such
interventions [4-7,3]. Similarly, contracting out of health
service provision to non-public enterprises appears prom-
ising, yet is also under-researched [8-11]. Our study looks
to investigate the potential of these two types of interven-
tion in tandem and in the context of the Lancet Neonatal
Survival Series findings [2].
The multi-faceted approach the trial adopts is also rooted
in the literature on public health interventions. McLeroy
et al. emphasize the need for public health interventions
to approach health problems on social and environmen-
tal levels, as well as at the individual level, in order to
obtain significant results [12]. Others have suggested that
multi-faceted health interventions have greater likelihood
of success than those which target individuals alone
[13,14].
Aside from the obvious motivation of rapidly and signifi-
cantly reducing neonatal mortality, these interventions
also have great promise in their sustainability and knock-
on effects. Investments in maternal education are largely
recognized to have long-term positive effects on child sur-
vival [15]. Similarly, there is evidence that infant morbid-
ity due to infection is significantly related to lifelong
disease-related impairment [16,17]. Improvement in
maternal education and reduction of infant morbidity as
a result of our intervention may yield long-term benefits
beyond the time-scale of the trial.
Background information on the trial area
Neonatal mortality constitutes 65% of all infant deaths in
India [18]. In the last three decades, consistent efforts
have been underway to reduce child mortality by empha-
sizing universal immunization, oral rehydration therapy
and control of respiratory tract infections. While infant
mortality in India has declined from 129 (per 1000 live
births) in 1970 to about 68 in 2000, the fate of neonates
has remained virtually unaltered: one out of 22 infants in
India does not reach the second month of life [19,20].
The state of Andhra Pradesh reports an aggregate neonatal
mortality rate (NMR) of 44 per 1000 live births [20].
There is very little reliable information quantifying neona-
tal survival rates in rural areas and tribal regions, although
these rates are known anecdotally to be even higher.
In 1998, a survey in the Mahabubnagar district of Andhra
Pradesh found infant mortality rates (IMR) to be much
higher than the national average. Summarised results of
this survey are shown in Table 2.
The Nagarkurnool division of Mahabubnagar had an
infant mortality rate of 140 per 1000 live births. It is
believed that approximately 50% of the infant deaths in
this division occur in the first month of life [20]. We have
chosen to conduct the trial in the Nagarkurnool division
in Mahabubnagar on account of the high mortality rate in
the area.
Any strategy to reduce neonatal mortality faces several
important obstacles. First, a substantial fraction of births
occur in unsafe conditions, usually at home. This reflects
longstanding traditions and lack of knowledge regarding
safe birth practices. Second, institutional care at public
health facilities is often geographically inaccessible. Third,
even if distance is not a problem, these facilities also sufferBMC Pediatrics 2007, 7:26 http://www.biomedcentral.com/1471-2431/7/26
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chronically from lack of medical practitioners and insuffi-
cient medical supplies. The problem faced is thus three-
fold: health knowledge, demand for health care, and
supply of good quality health care are all insufficient. The
trial intervention will augment all of these components in
order to assess whether, together, they substantially
reduce neonatal mortality rates.
Objectives
The aim of the trial is to test the hypothesis that a commu-
nity health promotion campaign, in combination with
improved supply of health services through contracting
out to the non-public sector, can lead to a substantial
reduction in neonatal mortality. The programme is
designed to improve health knowledge while enhancing
both demand for, and supply of, health care.
An important element of the trial is to evaluate the sus-
tainability of such a programme, its cost effectiveness, and
the potential to scale it up to meet needs in other high
neonatal mortality regions of Andhra Pradesh and else-
where.
Methods/Design
Endpoints of the study
The primary outcome of the study is neonatal mortality.
Secondary outcomes will include age at and cause of neo-
natal death, neonatal morbidity, maternal mortality and
morbidity, health service usage, costs and several process
and knowledge outcomes.
We will not be dividing foetal losses into miscarriages or
stillbirths for two reasons: firstly, gestational age is not
reliably reported; secondly, since women in the interven-
tion arm may report pregnancies earlier than women in
the control arm, we anticipate there could be a bias in the
measurement of gestational age, and this bias may differ
across the two arms of the trial.
Type of study
The trial is a cluster-randomised controlled trial involving
464 villages, with the village as the primary unit of ran-
domisation. This is an unblinded study as, following ran-
domisation, participants and their caregivers will be aware
of whether or not they are in an intervention village or
Table 1: Glossary of terms
Neonatal Mortality Rate Number of deaths during the first 28 completed days of life per 1000 live births in a given year.
Perinatal Mortality Rate The number of perinatal deaths per 1000 total births in a given year. The perinatal period starts at the beginning of 
foetal viability (28 weeks gestation) and ends at the end of the 7th day after delivery. Perinatal deaths are the sum of 
stillbirths plus early neonatal deaths.
Infant Mortality Rate Number of children dying under a year of age per 1000 live births in a given year.
Village Health Worker A local woman from the village trained primarily to deliver health education to eligible women and refer them to the 
midwife for antenatal pregnancy-related and postnatal services.
Gram Panchayat The Gram Panchayat is the executive organ of the Gram Sabha, an agency for planning and development at the village 
level. Its size varies from 15–30, and the population it covers also varies widely from 5,000 – 15,000. The members of 
the Panchayat hold office for 3–4 years. Every Panchayat has an elected President (Sarpanch) and the Vice president 
(Panchayat Secretary) The powers and functions of the Panchayat Secretary are very wide – they cover the entire 
field of civic administration, including sanitation and public health and of social and economic development in the 
villages.
Thanda Administratively, a thanda refers to a hamlet with a small population (around 100 households) vis-à-vis 'villages'. Each 
thanda is considered a part of a nearby village although the two habitations could be distant from each other.
Penta A Tribal Chenchu village is known as a "penta". Each penta consists of few huts that are spaced apart and are grouped 
together based on kinship pattern. The close relatives live nearby and the distant ones farther away. Their homes 
comprise of few belongings and are generally sparse and Spartan in appearance.
Anganwadi Worker Angan literally means "courtyard." Under the Integrated Child Development Services Scheme, there is an Anganwadi 
worker for each population of 1000 people. She is selected from the community and undergoes training in various 
aspects of health, nutrition and child development. She is a part time worker and is paid an honorarium for service 
including health checkups, immunisation, supplementary nutrition, health education, and informal preschool education 
and referral services for women in general and children below the age of 6 years.
DALYs Disability Adjusted Life Years is the sum of years of potential life lost due to premature mortality and the years of 
productive life lost due to disability.
Gram Sabha An assembly of all the adults of a given village which meets at least twice in a year. The Gram Sabha considers 
proposals for taxation, discusses annual programmes and elects members of the Gram Panchayat.
Table 2: District and division-level estimates of Infant Mortality 
Rate with 95% confidence levels in Mahabubnagar district of 
Andhra Pradesh [20]
Area IMR* 95% CI
Mahabubnagar district (overall) 115 107 – 122
Gadwal division 93 60 – 127
Mahabubnagar division 110 91 – 128
Narayanpet division 125 102 – 147
Wanarparthy division 62 35 – 89
Nagarkurnool division 140 117 – 163
*Infant mortality rate per 1000 live birthsBMC Pediatrics 2007, 7:26 http://www.biomedcentral.com/1471-2431/7/26
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control village. For outcomes such as death, this lack of
blinding is unlikely to lead to outcome assessment bias.
Randomisation
Villages will be stratified according to whether their travel
time to the nearest designated NPHC is less or greater than
one hour, and also into three groups according to whether
the village is thanda (2–3 km from the main village with
around 15 families), penta (20–30 km from the main vil-
lage with around 4–5 families) or non-tribal (a main vil-
lage). All villages will be randomly allocated, within each
of these six strata, to either the intervention or control
group.
Interventions – Intervention group
The trial will attempt to reduce neonatal mortality in the
intervention villages through a multi-level program: com-
munity health promotion and contracting out primary
and secondary health services to non-public providers. All
the services described below will be provided free to preg-
nant women and neonates in the intervention communi-
ties.
Community Health Promotion
To stimulate both adoption of healthy practices and
demand for care, the trial will implement a concerted
effort to promote health knowledge of communities in
the intervention arm. The three main components of this
are as follows:
• Training Village Health Workers and Midwives to deliver
antenatal services
The trial will select and train local women in the interven-
tion villages to serve as Village Health Workers (VHWs).
The person selected as VHW will usually be an Auxiliary
Nurse Midwife (ANM) or Traditional Birth Attendant
(TBA) already resident in the village. The person chosen
will be the most highly skilled available who is acceptable
to the communities in the village.
The VHW will be extensively trained by doctors and other
health professionals in domiciliary mother and baby care
along with postnatal and infant care. They will also be
trained in how to deliver antenatal care and conduct safe
deliveries at home. They will make home visits to preg-
nant women and to mothers with neonates. They will also
assist with home deliveries.
Approximately every two weeks, teams of two midwives
will visit intervention villages offering a package of ante-
natal care and services (referred to below as "fixed-day
services"). Midwives will be trained by doctors to deliver
clear, correct pregnancy and neonate-related health infor-
mation to mothers and their health care providers. They
will be trained in community mobilization and the use of
communication tools to address deep seated superstitions
and practices that have negative impacts on the health of
both mother and child. One midwife will act as the main
medium for communication of sound health information
to women in intervention villages. The other midwife will
deliver antenatal health checks and identify high risk preg-
nancies. She will also give advice to the women, relatives
and friends who accompany them on antenatal health
care issues and birth planning.
These midwives will supervise VHWs, offer guidance, and
conduct emergency deliveries if they occur during their
visits to the villages. In case of complications, the midwife
will be responsible for referring the mother/neonate in
distress to the next level of care.
Midwives based in NPHCs will organise and oversee
transportation for referred women.
The intervention team will train a total of approximately
250 VHWs (at least one for every village, in certain villages
we may have to train more than one) and approximately
20 midwives (16 midwives delivering fixed day services in
teams of two and 4 midwives based at NPHCs). They will
go through a orientation program and training of not less
than 10 days. This residential training will have both the-
oretical and practical components. It will be given by
experts in the field of maternal and neonatal health care.
Additionally midwives will be trained to update a trial-
specific health card provided to all eligible women in
intervention villages. These cards will track the various
services each woman in the intervention group has
received under the programme, including immuniza-
tions, participation in health groups, regular checkups
and hospitalisation. The VHWs and midwives will ensure
that these cards are filled correctly and on time by the var-
ious health care providers. The midwives will also keep a
record of the number of visits they have made to the vil-
lage, the number of women they have met, the number of
emergency deliveries with which they have assisted and
the number of cases they have referred to the NPHCs.
Midwives will also keep records of the nature of care they
provide to each mother and child attended.
For reinforcement of messages, the VHWs and midwives
will be given a manual to refer to for review. Regular meet-
ings will be held to allow them to share knowledge regard-
ing their work and problems encountered.
• Providing health education through a public informa-
tion campaignBMC Pediatrics 2007, 7:26 http://www.biomedcentral.com/1471-2431/7/26
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One of the most important contributors to poor maternal
and neonatal health is a lack of good health information.
This problem is particularly apparent in the local delivery
and infant rearing practices which are often in contradic-
tion of evidence-based good practice.
Health knowledge and awareness will be generated
through frequent village meetings and community events.
A health education campaign including theatre, films,
focus groups and other media will be launched to pro-
mote key themes related to maternal and child health in
each village. Folk culture in the form of song and dance
will also be adapted to convey important messages to
communities. All members of the community, not just
women eligible for the trial, will be targeted by these cam-
paigns.
As part of this campaign, VHWs will also make one to one
contact through home visits with mothers, providing
them with information related to their pregnancy and the
health status of their child. These visits will be conducted
on a periodic basis and will help reinforce good health
care and practice in women and children. During fixed-
day services, midwives will also answer health related que-
ries that the women may have during the course of her
pregnancy.
Midwives will also conduct regular village health meet-
ings during the days on which fixed-day services take
place. During these they will facilitate discussions, show
films and use posters, flip charts and flash cards with the
aim of promoting good health practices during and after
pregnancy. The exact nature and duration of communica-
tion exposure will be designed by a health communica-
tions expert.
• Organising women's participatory discussion groups
As there is strong evidence that participatory women's
groups can rapidly facilitate community-wide adoption of
hygienic practices, a vital responsibility of the VHWs in
intervention villages will be to facilitate good attendance
at group discussions on issues related to maternal and
neonatal health [6,7].
VHWs will organize eligible women from each village into
participatory discussion groups of a maximum size
between 15 and 20 individuals, creating multiple groups
if necessary to maintain appropriate group size. These
groups will meet during the day when fixed-day services
take part. The midwives will conduct these approximately
1–2 hour sessions at a time and venue suitable to a major-
ity of the women. Each session will contain ice-breakers, a
review of the last meeting's content, presentation of new
themes, reinforcement of themes through activities, dem-
onstrations, games and a small assignment. These discus-
sions will also be a forum where women can encourage
each other to access the trial services. Finally, the partici-
patory group will also serve as a group that provides valu-
able feedback about the various interventions.
Content for these sessions will include discussion of risk
factors for the baby and mother, safe delivery techniques,
causes of any recent deaths of neonates and mothers in
nearby regions, and other issues that are important in the
villages. The objective of these meetings is to improve
mothers' health knowledge, to encourage greater use of
fixed day services and other available health services, to
encourage safe delivery techniques and delivery of high
risk babies at the referral centre, and to give mothers a
forum to discuss solutions to important issues in maternal
and newborn health. This approach has been shown to be
very successful in a trial in Nepal [6].
Contracting out primary and secondary health services to non-public 
institutions
As outlined in the trial justification, the supply of primary
health care in the trial area is inadequate. Required
improvements to the public sector were estimated to be
prohibitively expensive, and evidence suggests the private
sector may be able to provide primary care which is supe-
rior to that provided by the public, and potentially at a
lower cost [11].
To increase supply of health services, the trial's interven-
tion will designate up to 5 NPHCs to provide primary and
secondary level care, made accessible through enhanced
emergency transportation. NPHCs will be selected which
are equipped with sufficient infrastructure and human
resources. It is imperative to provide women in the inter-
vention arm with quality services which are otherwise
unavailable or inadequate, as it is expected that the educa-
tional component of the intervention will lead to greater
awareness of the need for health services, and thus greater
uptake of these services.
The list of candidate NPHCs will be drawn-up based on
professional capability, existing infrastructure, and public
perception of the facility (public perception serves as a
way to introduce community participation in the selec-
tion process and to render the process transparent). Tie-
ups with such facilities will initially be for the period of 3
months after which a favourable review would lead to a 6
month renewal of the contract. Any kind of primary or
secondary service that an expectant mother would require
during her pregnancy and for one month of the life of her
baby would be covered by these facilities. By virtue of the
contractual agreement, these NPHCs would be expected
to provide around-the-clock service, admission to the gen-BMC Pediatrics 2007, 7:26 http://www.biomedcentral.com/1471-2431/7/26
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eral ward, food for the patient and one attendant, drugs,
and disposables.
This contract will be subject to a per-patient cost ceiling. A
rigorous monitoring system will buttress against over-bill-
ing and over-provision of services by the NPHCs.
Transportation will not be part of this contracting system,
but will be provided directly at the village level for pick-up
and drop off of patients at the NPHCs.
A detailed third party assessment of the quality of the serv-
ices by the NPHCs will be conducted periodically by a
committee of health and other professionals.
Interventions – Control group
As the control villages will not be offered the trial inter-
ventions unless and until they are shown to be effective,
yet data collection will still be required in these villages,
control villages will receive the Naandi Foundation's Girl
Child Support Programme [21], which is a component of a
larger "Ensuring Children Learn Programme" run by the
Naandi Foundation in two other states of India. The Girl
Child Support component will provide academic and
material support to girls between the ages of six and nine.
This intervention is aimed at creating opportunities for
young girls to attend and remain in school.
It is anticipated that these interventions in the control
group will have negligible impact on neonatal mortality.
The fact that these interventions are being carried out,
however, may improve the extent and quality of the data
collected in the control villages.
Duration
The trial will run over a period of three years.
Enrolment – Trial site(s) and participants
The trial site is the Nagarkurnool division of Mahabubna-
gar district in the Indian state of Andhra Pradesh. The trial
will involve only those villages in the division with a pop-
ulation of less than 2,500 people. This criterion was
decided upon in light of the fact that larger villages and
towns generally have better access to health services, lower
neonatal mortality rates, and therefore less potential to
benefit from the interventions. Under this criterion, a
total of 464 villages will be eligible for the trial with a total
population of approximately 300,000 people.
Enrolment – Inclusion criteria
A woman is eligible for inclusion in the trial if she satisfies
the following criteria: i) she is married and less than 50
years old, ii) she or her husband have not had a family
planning operation, iii) she is resident in one of the 464
villages at the time of a baseline survey that is to be carried
out immediately prior to randomization, and iv) she
meets all conditions for consent outlined in the consent
section. Once the baseline survey has been carried out and
the eligible women enrolled, the only permitted addition
to the trial will be those women who marry into a trial vil-
lage. Women will not be added or removed from the list
as a result of either temporary or permanent migration
from the village at which they are initially registered.
Only those children of eligible women whose estimated
date of delivery at enumeration is at least six months after
randomization will be included in the trial. As training
and establishment of services in intervention villages will
require time to be achieved, this lag in measurement is
necessary to ensure exposure to the intervention.
Enrolment – Exclusion criteria
Women and their children will be excluded from the trial
if the woman in question is unmarried, if she is aged 50 or
over at the time of the baseline survey, if she or her hus-
band went through a family planning operation, or if she
refuses to participate in the baseline survey.
Enrolment – Sources/methods of enlisting participants in 
trial
An enumerator will be identified and trained in each of
the 464 villages. After training, this individual will com-
pile a list of all eligible women in their village and carry
out a baseline survey of all such women. The starting
point for the list of eligible women will be the official list
of residents held by the Anganwadi Worker for the village.
Enrolment – Dealing with migration
The population of the villages eligible for the trial will not
remain static over the duration of the trial. Migration will
occur for a number of different reasons. These will include
permanent migration (which is relatively rare), marriage
into a trial village, and temporary migration. As men-
tioned above, those women who marry into one of the
464 eligible villages during the duration of the trial will be
considered eligible for participation in the trial. Tempo-
rary migration includes seasonal migration for work,
which is very common in the area under scrutiny, and
selective migration in order to give birth in the village
where the pregnant woman's mother lives. This selective
migration is expected to be nearly universal for women
expecting their first child, but much more limited for later
deliveries. In addition, some women might migrate
because of a wish to benefit from the services provided in
intervention villages, although it is anticipated that this is
very unlikely.
In total we anticipate that around two-thirds of the deliv-
eries of women enrolled in the trial will take place in the
village of enumeration. Of the remaining one third, someBMC Pediatrics 2007, 7:26 http://www.biomedcentral.com/1471-2431/7/26
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will move to a village of the same type as their initial vil-
lage (control or intervention), some will move to a loca-
tion beyond the scope of the study, and some will move
from intervention to control or vice-versa. This migration
poses several challenges to the design of, data collection
in, and analysis of the trial.
Because it is anticipated that the benefits of the interven-
tion programme will occur throughout pregnancy and not
just at the time of delivery, the trial has been designed to
compare neonatal mortality rates according to village of
residence rather than village at which delivery takes place.
This allows each woman's village to be specified prior to
randomisation, which reduces the potential for bias. A
structural bulwark will ensure that only those women
who are resident in intervention villages at the time of
enumeration (along with those who marry in) receive the
programme of services. Operationally those women who
move from a control to an intervention village pose
potentially the greatest problem. These women would
normally not have subsidised access to non-public health
services. If such exclusions have a negative impact on trial
activities and morale in particular villages, then excep-
tional provision of non-public care will be decided upon
in a case-by-case basis by the supervisors.
Enrolment – Losses to follow-up
Data will be collected on each pregnancy at the enumera-
tion village. It is not anticipated that women who do not
migrate will voluntarily withdraw from the trial. When a
woman migrates this will be documented and data col-
lected when she returns. Every effort will be made to
record data from all women who are included at enumer-
ation to ensure that bias due to migration-related loss of
observations is kept to a minimum. Women who migrate
beyond the scope of the trial will be sought out for infor-
mation. In case of inability to locate an enumerated
woman, we will interview two of her relatives for birth
information. Nonetheless, it is recognised that migration
will both reduce the observed effect of the intervention
and lead to some loss of information. This has been taken
into account in the statistical power calculation.
Consent
For this trial we will employ three tiers of consent: state,
Panchayat, and individual.
• At the state level, approval of the protocol has been
obtained from the Department of Health & Family Wel-
fare of the government of Andhra Pradesh.
• Consent will also be obtained from each Panchayat in
the trial area. The Panchayat is a democratically elected
body that governs a small group of villages. This is the
smallest unit of government in rural India. In all villages
in the trial, consent will be obtained from the Panchayat
in the following manner. These local bodies will convene
their general body meetings (also called the Gram Sab-
has). The protocol of the trial will be explained to the vil-
lagers in their local language. Consent will be given in oral
form during a Panchayat meeting with written documen-
tation of the approval given by the Panchayat leader. This
process of obtaining consent through meetings with
approval of the 'guardians' of the clusters is common in
trials in which the intervention is delivered at the level of
a cluster and it is not possible to obtained for informed
consent for randomisation from individuals within the
cluster [22].
• Given this process, women who are asked and agree to
take part in the enumeration are considered to have given
their informed consent to participate in the trial. Women
not living in the villages at that point who subsequently
fulfil the eligibility criteria will be informed about the
study and asked if they agree to be added to the list.
Sample size calculation
The sample size has been calculated to give 80% statistical
power to show a reduction in neonatal mortality that is
statistically significant using a conventional 2-sided sig-
nificance level of 5% if the true effect of the package of
interventions is to reduce neonatal mortality by 25%. We
assumed 4.38% neonatal mortality in the control villages
(and hence 3.29% neonatal mortality in the intervention
villages), an average population of 659 per village, a birth
rate of 23 per 1000 population (giving rise to an average
of 38 births per village over a period of 2.5 years) and an
intra-cluster correlation coefficient of 0.00644 [20,6].
Under these assumptions we require 330 villages to detect
a 25% reduction in neonatal mortality.
In the trial area, however, women who are expecting their
first child usually move back to their mother's village
around one to three months before the expected date of
delivery. This migration could reduce the measured effect
of intervention if women move from control villages to
intervention villages and vice-versa. According to the
NFHS-2, 36% of all births are first births in Andhra
Pradesh. We assume that 90% of these women temporar-
ily migrate and on the basis of this that 8% of control
women actually deliver in an intervention village, whilst
24% of intervention women will deliver in non-interven-
tion villages (8% in control group villages and 16% in vil-
lages outside of the study area) [20]. Assuming that both
groups incur half the benefits of the intervention, the
expected neonatal mortality rates in the two groups
become 4.34% and 3.42%. Under this scenario 464 vil-
lages will still give 80% statistical power to show a reduc-
tion in neonatal mortality that is statistically significant at
the 5% level.BMC Pediatrics 2007, 7:26 http://www.biomedcentral.com/1471-2431/7/26
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Analysis strategies
The main analysis will assess the effect of the interven-
tions on the primary and secondary outcomes. Primary
analysis of the outcome(s) will follow the intention to
treat principle (i.e. the participants will remain in the
group they were randomised to and not analysed accord-
ing to the interventions actually received), and will
account for clustering.
For the primary outcome (neonatal mortality), the rela-
tive risk with a 95% confidence interval will be reported,
taking appropriate account of clustering. A generalised
linear model (without adjustment for covariates) using
robust standard error estimates will be used to carry out
this analysis. A further analysis will adjust for distance to
nearest healthcare centres (public and private) and migra-
tion.
For secondary binary outcomes, including neonatal mor-
bidity, maternal mortality and morbidity, and health serv-
ice usage, relative risks will be estimated in an analogous
fashion. For continuous outcomes t-tests with robust SEs
will be carried out. ANCOVA (with robust standard
errors) will be used where baseline adjustment is required.
Bootstrapping will be used for non-normal outcomes and
Cox models for survival analysis. A full analysis plan is
given in the operations manual.
Ethical Approval
The protocol has received ethical approval from the insti-
tutional review board of the LV Prasad Eye Institute,
Hyderabad, India, which is affiliated with the Indian
Council of Medical Research(Ethics Reference Number:
LEC07002) as well as from the ethics committee of the
London School of Hygiene and Tropical Medicine (appli-
cation number: 5166).
Discussion
Administrative Structures – The implementation team
The trial is constructed with independent research and
services teams that are responsible for data collection
needed to analyze outcomes, and the implementation of
the interventions, respectively. The services team will be
responsible for implementing the interventions. They will
conduct activities to assess the implementation of inter-
ventions in their regions, such as collecting survey data,
and tracking the use of various health services by pregnant
women in villages. The people employed in the research
team will have no role in the services component of the
trial and vice-versa. Separating service delivery activities,
which occur only in the intervention villages, from
research activities, which will occur in both control and
intervention villages, is a bulwark against contamination
of our data for analysis. These groups are described in fur-
ther detail below.
The Service Delivery Team will be responsible for all service
delivery activities in the intervention villages. The mem-
bers of this team include:
a. A Programme Coordinator who will head the team.
b. Village Health Workers (VHWs), women who will be
responsible for delivering antenatal and health education
to the village assigned to her. In her village, the VHW will
also track high risk mothers and refer them to the NPHCs.
c. Midwives who will support antenatal care at the village
level and conduct safe deliveries. They will accompany
high risk pregnancy cases to the NPHCs. They will also be
responsible for conducting village visits and performing
health communication activities.
d. Programme Supervisors and Programme Officers who will
oversee the day-to-day operations and monitor the field
staff.
The Research Team will track pregnant women and their
babies, as well as perform data collection and monitoring,
in both intervention and control villages. The members of
this team include:
a. A Research Coordinator who will lead the team.
b. A Research Officer who will validate collected data and
monitor the field staff.
c. Enumerators in each village who will identify eligible
women and track pregnancies.
d. Data Supervisors who will monitor the enumerators and
obtain detailed follow-ups on pregnancy outcomes (e.g.
deliveries, still births, miscarriages and neonatal death).
Administrative Structures – Trial management
The trial will be supervised by the Trial Steering Commit-
tee and the Trial Management Group. Day to day activities
will be the responsibility of the Naandi Foundation with
support from Effective Intervention and the LSHTM where
appropriate.
The Trial Management Group will include a Trial Man-
ager, Trial Programmer, Database Manager and Trial Stat-
istician. This group will meet monthly, either face-to-face
and/or by telephone, to ensure the efficient day-to-day
running of the trial, to prepare reports for the steering
committee, and to organize and service the data monitor-
ing and ethics committee.BMC Pediatrics 2007, 7:26 http://www.biomedcentral.com/1471-2431/7/26
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Administrative Structures – Trial Coordinating Centre
The Naandi Foundation will act as the local Trial Coordi-
nating Centre and be responsible for recruitment, imple-
menting interventions, and handling administrative
matters once participants are being entered.
Administrative Structures – Trial Steering Committee
The Trial Steering Committee (TSC) will meet periodically
to discuss the overall progress of the trial. It will include
all principal investigators, trial manager, one or two expe-
rienced investigators not otherwise involved in the trial,
and a statistician. The group will meet initially to finalize
the protocol and organisation. Once the trial is running,
the group will meetregularly to discuss issues such as
recruitment progress and protocol deviations from the
Data Monitoring Committee. The TSC will evaluate this
information and take or refrain from action accordingly.
Administrative Structures – The Data Monitoring 
Committee
The Data Monitoring Committee (DMC) will be com-
pletely independent of the trial and will meet regularly to
review interim results. The principal role of the DMC is to
monitor accumulating data by random allocation and
alert the organizers of the trial if they think patterns in the
data – indicating benefits, hazards or both – are suffi-
ciently persuasive to warrant either closing recruitment to
a trial or changing the protocol. The DMC will include a
biostatistician and clinicians with expertise in the topic
under trial. Data will be given to the DMC on a confiden-
tial basis by the trial statistician.
Interim analyses
Interim analyses will be pre-specified, but may be
amended if requested by the DMC. The analyses for the
DMC will be performed by the trial statistician only and
no other members of the trial research group will have
access to the results.
The DMC will first assess the data when data on the out-
come of contributing births (i.e. not including births in
the first six months post randomisation) from no less
than one full year is available. A Peto-Haybittle rule will
be utilised to help the DMC to assess whether to recom-
mend that the trial should be stopped for efficacy or harm,
but the DMC will also take into account the balance of
risks and benefits as well as consistency with external evi-
dence [23,24].
Surveillance/data collection
In each village, data will be collected by the Enumerator
on a monthly basis on paper forms which will then be
entered into a database. Data Supervisors will perform fol-
low-up interviews according to data collected by the enu-
merator, to determine pregnancy outcomes and relevant
information which is then reported to the Coordinating
Centre. Each pregnancy will be followed until at least six
weeks after delivery. The Coordinating Centre will com-
pile the data and perform internal checks for data integrity
and consistency.
The trial will use a computerised system for data manage-
ment to keep track of the flow of participants in the trial
as well as for recording the continuous flow of informa-
tion to and from participants. The system will provide effi-
cient data validation, quality control and standardised
management reports.
Quality control programme
To ensure quality of clinical centres, data handling and
processing in the coordinating centre, a quality control
programme will be established to run concurrently with
the intervention. This will include a system of data check-
ing, audit trails (detailed logs showing data which have
been changed, the reason for any change, who made the
change and when), and source verification procedures. In
the process, information about adverse events, compli-
ance and protocol deviations, contamination, co-inter-
ventions, and documentation of losses and dropouts will
be systematically recorded.
Data and safety monitoring
The TSC will ensure the safety of individual patients par-
ticipating in the trial by setting up and running the trial in
accordance with good practice. Neither the TSC nor any
other team member involved with running the trial will
have sight of accumulating data by allocation during the
course of the trial.
Economic evaluation and sustainability of measures post-
intervention
An important goal of the study is to analyze the costs and
benefits of the approach, and the sustainability of the out-
comes. We will conduct a cost-effectiveness analysis,
measured in terms of the cost per disability adjusted life
year (DALY) saved, when the trial is completed. In this
analysis, we will compare the effects of the trial's interven-
tion with those of other interventions targeting neonatal
death.
Ethics/protection of human subjects – Stopping Guidelines
Guidelines are outlined in the section above describing
the data monitoring committee.
Ethics/protection of human subjects – Research 
governance and good clinical practice
The trial will comply with all relevant legal and profes-
sional standards. These include ethics (especially protect-
ing patient confidentiality); science (ensuring research is
well designed); information (ensuring that research find-BMC Pediatrics 2007, 7:26 http://www.biomedcentral.com/1471-2431/7/26
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ings are published and accessible); health and safety
(ensuring the safety of staff and participants); and finance
(being accountable for spending research funds).
Ethics/protection of human subjects – HIV/AIDS
In both arms of the trial, mothers/women who appear
tobe at high risk for HIV/AIDS will be advised toget coun-
selled and tested atdesignated government VCTCs (volun-
tary counselling and testing centres). The trial team will
facilitate easy accessto these centres by providing trans-
port and liaison with professionals at the centres.
Publication policy – Reporting and dissemination
Prior to their submission or application for presentation,
all manuscripts, posters or oral presentations, and other
reports of the outcomes of this research effort will be
approved by a majority of the TSC. All publications will
include a formal acknowledgement that the trial was
designed and executed by the LSHTM, the Naandi Foun-
dation, the NICE Foundation, and Effective Intervention,
and that financial support was provided by Effective Inter-
vention. The primary report of the trial will follow the
reporting guidelines in the CONSORT Statement for clus-
ter RCTs [25].
Publication policy – Authorship
The authorship of manuscripts, posters, oral presenta-
tions, and any other reports of the results of this study will
be guided by the criteria for authorship formulated by the
International Committee of Medical Journal Editors as
published in its "Uniform Requirements for Manuscripts
Submitted to Biomedical Journals" [26]. According to
these requirements, the authors should meet the follow-
ing criteria: each author should have participated suffi-
ciently in the work to take public responsibility for the
content. Authorship credit should be based only on sub-
stantial contributions to (a) conception and design, or
analysis and interpretation of data; and to (b) drafting the
article or revising it critically for important intellectual
content; and on (c) final approval of the version to be
published. Conditions (a), (b), and (c) must all be met.
As a general, but not absolute, rule, at least one individual
from each of the four partner organizations – the Naandi
Foundation, Effective Intervention, the NICE Foundation
and the LSHTM – will be authors for all publications that
result from this research.
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